Loading
A phase 1 trial of STX-0712 run by Solu Therapeutics, Inc, now recruiting.
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) is a phase 1 interventional study registered as NCT06950034 by Solu Therapeutics, Inc, with 105 participants planned, started 2025-03-13. Conditions recorded: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Refractory Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemias, Refractory Acute Myeloid Leukemia (AML) and Acute Monocytic Leukemia. Interventions recorded: STX-0712.
Shares Solu Therapeutics and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Shares Leukaemia (all types), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/